SCHEMBL2569963

SCHEMBL2569963

Nc1nc(NCc2ccc(F)cc2)cc(-c2cc(C3CC3)[nH]n2)c1N

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 6/20 0.48
MKNK1 Q9BUB5 2/20 0.43
MKNK2 Q9HBH9 2/20 0.43
HRH4 Q9H3N8 1/20 0.39
HRH3 Q9Y5N1 1/20 0.39
IGF1R P08069 5/20 0.39
KCNQ3 O43525 1/20 0.39
KCNQ2 O43526 1/20 0.39
ABCB11 O95342 1/20 0.39
ESR1 P03372 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
HTR1A P08908 1/20 0.39
ADRA2A P08913 1/20 0.39
ADORA3 P0DMS8 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
ALOX15 P16050 1/20 0.39
NFKB1 P19838 1/20 0.39
TBXA2R P21731 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2566466 0.83 NTRK1 (0.48) NTRK1MKNK1MKNK2IGF1RNUAK1
SCHEMBL4696420 0.82 NTRK1 (0.51) NTRK1MKNK1MKNK2IGF1RCYP1A2
SCHEMBL2577693 0.75 PRKCQ (0.44) NTRK1MKNK1MKNK2IGF1RCYP1A2
SCHEMBL4698162 0.75 NTRK1 (0.44) NTRK1MKNK1MKNK2IGF1RKCNQ3
SCHEMBL2207390 0.74 NTRK1 (0.44) NTRK1MKNK1MKNK2HRH4HRH3
SCHEMBL2571347 0.73 HTT (0.46) NTRK1MKNK1MKNK2IGF1RCYP1A2
SCHEMBL4696504 0.72 CYP1A2 (0.49) NTRK1MKNK1MKNK2CYP1A2CYP3A4
SCHEMBL3137650 0.71 HTT (0.48) NTRK1MKNK1MKNK2CYP1A2CYP3A4
SCHEMBL2490728 0.71 NTRK1 (0.64) NTRK1IGF1RNUAK1NTRK3NTRK2
SCHEMBL3137390 0.69 HTT (0.46) NTRK1MKNK1MKNK2IGF1RCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2383268-B1 PYRAZOLYLAMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS ASTRAZENECA AB (SE) 2015-09-02 EP disclosed
EP-2383268-A1 Pyrazolylaminopyridine derivatives useful as kinase inhibitors AstraZeneca AB (SE) 2011-11-02 EP disclosed
EP-1853588-B1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2008-06-18 EP disclosed
US-20080108669-A1 Use 541 ASTRAZENECA AB (SE) 2008-05-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108669-A1 Use 541 TRPV1, P2RX3, P2RX5 NTRK1 3837/4885MKNK1 2486/4885MKNK2 2644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.